Literature DB >> 26494646

A helping hand for regadenoson tests.

Preeti Kansal1, Thomas A Holly2.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26494646     DOI: 10.1007/s12350-015-0298-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  15 in total

1.  A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.

Authors:  Matthew W Parker; Donna Chelle Morales; Hanna B Slim; Alan W Ahlberg; Deborah M Katten; Giselle Cyr; Shishir Mathur; Afrooz Ardestani; Dimitrios Barmpouletos; Geeta Swamy Iyah; Steven M Borer; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2012-11-28       Impact factor: 5.952

2.  Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.

Authors:  Randall C Thompson; Harshal Patil; Elaine C Thompson; Gregory S Thomas; Mohammed Al-Amoodi; Kevin F Kennedy; Kevin A Bybee; A Iain McGhie; James H O'Keefe; Lisa Oakes; Timothy M Bateman
Journal:  J Nucl Cardiol       Date:  2012-12-12       Impact factor: 5.952

3.  Pharmacologic stress perfusion imaging with adenosine: role of simultaneous low-level treadmill exercise.

Authors:  Habib Samady; Frans J Th Wackers; Tammy M Joska; Barry L Zaret; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

4.  Impact of an abbreviated adenosine protocol incorporating adjunctive treadmill exercise on adverse effects and image quality in patients undergoing stress myocardial perfusion imaging.

Authors:  M D Elliott; T A Holly; S M Leonard; R C Hendel
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

5.  Complications of exercise and pharmacologic stress tests: differences in younger and elderly patients.

Authors:  A Hashimoto; E L Palmar; J A Scott; S A Abraham; A J Fischman; T L Force; J B Newell; C A Rabito; G D Zervos; T Yasuda
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

6.  Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

Authors:  Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2010-04-23       Impact factor: 5.952

Review 7.  Regadenoson: a focused update.

Authors:  Gopal Ghimire; Fadi G Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

8.  Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

Authors:  M I Ross; E Wu; J T Wilkins; D Gupta; S Shen; D Aulwes; K Montero; T A Holly
Journal:  J Nucl Cardiol       Date:  2013-02-13       Impact factor: 5.952

9.  Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.

Authors:  Sara L Partington; Viswanatha Lanka; Jon Hainer; Ron Blankstein; Hicham Skali; Daniel E Forman; Marcelo F Di Carli; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2012-05-08       Impact factor: 5.952

10.  The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging.

Authors:  Gregory S Thomas; Randall C Thompson; Michael I Miyamoto; Tze K Ip; Deborah L Rice; Douglas Milikien; Hsiao D Lieu; Vandana S Mathur
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

View more
  1 in total

Review 1.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology in 2017. Part 2 of 2: Myocardial perfusion imaging.

Authors:  Fadi G Hage; Wael A AlJaroudi
Journal:  J Nucl Cardiol       Date:  2018-04-16       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.